Item 8.01. Other Events.
On October 27, 2009, PolyMedix, Inc. (the "Company") announced the results of
its Phase 1B clinical study for its anticoagulant reversing agent, PMX-60056. A
copy of the Company's press release announcing the results of its clinical study
is filed herewith as Exhibit 99.1 and is in its entirety incorporated in this
Item 8.01 by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Sign Up for a Free Trial to the NEW EDGAR Online Pro Detailed
SEC, Financial, Ownership and Offering Data on over
12,000
U.S. Public Companies. Actionable
and easy-to-use with searching, alerting, downloading
and more. Request
a TrialSign
Up Now
Add
PYMX.OB to Portfolio
Set Alert
Email to a
Friend